Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021
May 03, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 3, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
Addex Increases Issued Share Capital to Create Treasury Shares
April 26, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 26, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
Addex to Participate at the 4ᵗʰ Annual Neuroscience Innovation Forum
April 26, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 26, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
Addex to Present at the 20th Annual Needham Virtual Healthcare Conference
April 13, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 13, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission
April 08, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 8, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Reports Full Year 2020 Financial Results and Provides Corporate Update
March 11, 2021 01:00 ET
|
Addex Therapeutics
Strong cash and cash equivalents position at Dec 31, 2020 of $20.2M (CHF18.7M) Balance sheet further strengthened by $11.5M fundraising on January 11, 2021Three clinical studies in neurology programs...
Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021
March 09, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 9, 2021 – Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that...
Addex to Present at the H.C. Wainwright Global Life Sciences Conference
March 04, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 4, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million
February 17, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, February 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder
February 16, 2021 01:00 ET
|
Addex Therapeutics
Review from Linköping University Published in Alcohol and Alcoholism Journal Geneva, Switzerland, February 16, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical...